UPM will produce two generic drugs for Amerigen Pharmaceuticals at a former Pfizer facility under a new 10 year supply contract.
UPM will make the drugs at a 475,000 square foot manufacturing facility in Bristol, Tennessee that it acquired from Pfizer in July of 2013 and, eventually, all of these products will be made at this facility.
The site offers large scale commercial capabilities for manufacturing and packaging oral solid doses. UPM also manufactures Pfizer products at the site.
Over $30m (€21m) has been invested in the site over the past four years to upgrade and add new manufacturing and support facilities.
“UPM has been working with Amerigen for the past three years providing development services for their significant pipeline of ANDA products,” John Gregory, CEO of Gregory Pharmaceutical Holdings, said.
New Jersey-based Amerigen also has manufacturing facilities in China.
“We have a strong working relationship with their company and are impressed with their technical team and their business development approach. We believe this agreement cements our partnership with Amerigen. Also, it is another example of UPM’s transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients,” he added.